By Fineline Cube 
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to the US Food and Drug Administration (FDA) for LAE102, an Activin Receptor Type 2 A (ActRIIA)-targeted monoclonal antibody (mAb) co-developed with Eli Lilly & Co. (NYSE: LLY).
Collaboration Details
Under the agreement signed between Laekna and Lilly in November last year, Lilly will conduct the Phase I study for LAE102. The drug received FDA approval for obesity studies in April 2024 and is scheduled to commence clinical trials in the second quarter of 2025.
Global Rights and Development
Laekna retains global rights for LAE102, positioning the company to leverage the therapeutic potential of this innovative monoclonal antibody. The collaboration with Lilly underscores Laekna’s commitment to advancing treatments for metabolic disorders through strategic partnerships.-Fineline Info & Tech